Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/07/21
Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/29/21
Guardant Health to Participate in the BofA Securities 2021 Healthcare ConferenceBusiness Wire • 04/29/21
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung CancerBusiness Wire • 04/27/21
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced CancersBusiness Wire • 04/10/21
Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage CancerBusiness Wire • 04/01/21
Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx TestBusiness Wire • 03/30/21
Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal CancerBusiness Wire • 03/24/21
Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid CancersBusiness Wire • 03/02/21